INTRODUCTION: Renal cell carcinoma (RCC) is one of the most prevalent cancers in kidney transplant recipients (KTR). The hereditary background of RCC in native kidneys has been determined, implicating its clinical importance. MATERIALS AND METHODS: This retrospective single-center pilot study aimed to identify a potential genetic predisposition to RCC of the transplanted kidney and outcome in KTR who underwent single kidney transplantation between January 2000 and December 2020 and manifested RCC of the transplanted kidney. Next-generation sequencing (NGS) based germline genetic analysis from peripheral blood-derived genomic DNA (gDNA) was performed in both the recipient and donor using a gene panel targeting 226 cancer predisposition genes. RESULTS: The calculated incidence of RCC of the transplanted kidney among 4146 KTR was 0.43%. In fifteen KTR and donors, NGS was performed. The mean KTR age at transplantation and the diagnosis of RCC was 50.3 years (median 54; 5-67 years) and 66 years (median 66; 24-79 years), respectively. The mean donor age at transplantation and graft age at RCC diagnosis was 39.7 years (median 42; 7-68 years) and 50.2 years (median 46; 20-83 years), respectively. The mean follow-up after RCC diagnosis was 47 months (median 39.1; 0-112 months). Papillary RCC was the most prevalent (n = 8), followed by clear cell RCC (n = 6) and unspecified RCC (n = 1). Thirteen RCCs were low-stage (pT1a/b) diseases, one was pT3, and one was of unknown stage. Most RCC was higher graded. No germline pathogenic cancer-predisposition variant was found in either KTR or donors except for several variants of uncertain significance. CONCLUSION: RCC of the transplanted kidney is very rare. Germline cancer-predisposition testing has identified several variants of uncertain significance, but no germline genetic predisposition to graft RCC in KTR. Further research is needed to assess the clinical relevance of genetic testing for cancer risk in KTR.

1st Faculty of Medicine Institute of Biology and Medical Genetics Charles University and General University Hospital Prague Prague Czech Republic

1st Faculty of Medicine Institute of Medical Biochemistry and Laboratory Diagnostics Charles University and General University Hospital Prague Prague Czech Republic

1st Faculty of Medicine Institute of Pathological Physiology Charles University Prague Czech Republic

Department of Clinical and Transplant Pathology Institute for Clinical and Experimental Medicine Prague Czech Republic

Department of Nephrology Institute for Clinical and Experimental Medicine Prague Czech Republic

Department of Pediatrics and Inherited Metabolic Disorders 1st Faculty of Medicine Charles University and General University Hospital Prague Prague Czech Republic

Zobrazit více v PubMed

Krynitz B, Edgren, Lindelöf B, Baecklund E, Brattström C, Wilczek H, Smedby KE. Risk of skin cancer and other malignancies in kidney, liver, heart and lung transplant recipients 1970 to 2008–A Swedish population-based study. Int J Cancer. 2013;132(6): 1429–1438. doi: 10.1002/ijc.27765 PubMed DOI

Cheung CY, Tang SCW. An update on cancer after kidney transplantation. Nephrol Dial Transplant. 2019. Jun 1;34(6):914–920. doi: 10.1093/ndt/gfy262 PubMed DOI

Vajdic CM, McDonald SP, McCredie MRE, van Leeuwen MT, Stewart JH, Law M et al.. Cancer incidence before and after kidney transplantation. JAMA. 2006. Dec 20;296(23):2823–31. doi: 10.1001/jama.296.23.2823 PubMed DOI

Datta D, Contreras AG, Basu A, Dormond O, Flynn E, Briscoe DM, et al.. Calcineurin inhibitors activate the proto-oncogene Ras and promote protumorigenic signals in renal cancer cells. Cancer Res 2009; 69:8902–9. doi: 10.1158/0008-5472.CAN-09-1404 PubMed DOI PMC

Au E, Wong G, Chapman JR. Cancer in kidney transplant recipients. Nat Rev Nephrol. 2018. Aug;14(8):508–520. doi: 10.1038/s41581-018-0022-6 PubMed DOI

Escudier B, Porta C, Schmidinger M, Rioux-Leclerq N, Bex A, Khoo V et al.; Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30(5):706–720. doi: 10.1093/annonc/mdz056 PubMed DOI

Bonsib SM. Renal cystic diseases and renal neoplasms: a mini- review. Clin J Am Soc Nephrol. 2009;4(12):1998–2007. doi: 10.2215/CJN.02020309 PubMed DOI

Mühlfeld A, Boor P. Aquired cystic kidney disease and malignant neoplasms. In: Feehally J, Floege J, Tonelli M, et al.. Comprehensive Clinical Nephrology. 6th ed. Elsevier; 2019:1022–1027.

Llamas F, Gallego E, Salinas A, Virseda J, Pérez J, Ortega A et al.. Sarcomatoid renal cell carcinoma in a renal transplant recipient. Transplant Proc. 2009. Dec;41(10):4422–4. doi: 10.1016/j.transproceed.2009.08.066 . PubMed DOI

Krishan A, Wong G, Teixeira-Pinto A, Lim WH. Incidence and outcomes of early cancers after kidney transplantation. Transpl Int. 2022. May 3;35:10024. doi: 10.3389/ti.2022.10024 PubMed DOI PMC

Leveridge M, Musquera M, Evans A, Cardella C, Pei Y, Jewett M et al.. Renal cell carcinoma in the native and allograft kidneys of renal transplant recipients. J Urol. 2011;186(1):219–223. doi: 10.1016/j.juro.2011.03.032 PubMed DOI

Ranassinghe WK, Suh N, Hughes PD. Survival Outcomes in Renal Transplant Recipients With Renal Cell Carcinoma or Transitional Cell Carcinoma From the ANZDATA Database. Exp Clin Transplant. 2016. Apr;14(2):166–71. doi: 10.6002/ect.2015.0192 PubMed DOI

Frasca GM, Sandrinii S, Cosmai L, Porta C, Asch W, Santoni M et al.. Renal cancer in kidney transplanted patients. J Nephrol. 2015. Dec;28(6):659–68. doi: 10.1007/s40620-015-0219-8 PubMed DOI

Benett WM, Simonich EL, Garre AM, McEvoy KM, Farinola MA, Batiuk TD. Renal cell carcinoma in renal transplantation: The case for surveillance. Transplant Proc. 2017. Oct;49(8):1779–1782. doi: 10.1016/j.transproceed.2017.06.031 PubMed DOI

Guleryuz K, Doerfler A, Codas R, Coffin G, Hubert J, Lechevallier E, et al.. A national study of kidney graft tumor treatments: Toward ablative therapy. Surgery. 2016. Jul;160(1):237–244. doi: 10.1016/j.surg.2016.01.022 PubMed DOI

Eccher A, Girolami I, Motter JD, Marletta S, Gambaro G, Momo REN et al.. Donor-transmitted cancer in kidney transplant recipients: a systematic review. J Nephrol. 2020. Dec;33(6):1321–1332. doi: 10.1007/s40620-020-00775-4 PubMed DOI PMC

Adeniran AJ, Shuch B, Humphrey PA. Hereditary Renal Cell Carcinoma Syndromes: Clinical, Pathologic, and Genetic Features. Am J Surg Pathol. 2015. Dec;39(12):e1–e18. doi: 10.1097/PAS.0000000000000562 PubMed DOI

Shuch B, Vourganti S, Ricketts CJ, Vocke CD, Gautam R, Merino M et al.. Vascular Endothelial Growth Factor Receptor-Targeted Therapy in Succinate Dehydrogenase C Kidney Cancer. J Clin Oncol. 2016. Mar 20;34(9):e76–9. doi: 10.1200/JCO.2013.51.0214 PubMed DOI PMC

Huang KL, Mashl J, Wu Y, Ritter DI, Wang J, Oh C et al.. Pathogenic Germline Variants in 10,389 Adult Cancers. Cell. 2018. Apr 5;173(2):355–370.e14. doi: 10.1016/j.cell.2018.03.039 PubMed DOI PMC

Lui ST, Shuch B. Genetic Testing in Kidney Cancer Patients: Who, When, and How? Eur Urol Focus. 2019. Nov;5(6):973–976. doi: 10.1016/j.euf.2019.09.005 PubMed DOI

Carlo MI, Mukherjee S, Mandelker D, Vijai J, Kemel Y, Zhang L et al.. Prevalence of Germline Mutations in Cancer Susceptibility Genes in Patients With Advanced Renal Cell Carcinoma. JAMA Oncol. 2018. Sep 1;4(9):1228–1235. doi: 10.1001/jamaoncol.2018.1986 PubMed DOI PMC

Santos M, Lanillos J, Roldan-Romero JM, Caleiras E, Montero-Conde C, Cascón A et al.. Prevalence of pathogenic germline variants in patients with metastatic renal cell carcinoma. Genet Med. 2021. Apr;23(4):698–704. doi: 10.1038/s41436-020-01062-0 PubMed DOI

Nguyen CB, Knaus C, Li J, Accardo ML, Koeppe E, Vaishampayan UN et al.. Pathogenic germline muttional landscape in patients with renal cell carcinoma and associated clinicopathologic features. JCO Precis Oncol. 2023. Sep:7:e2300168. doi: 10.1200/PO.23.00168 PubMed DOI

Ljungberg B, Albiges L, Abu-Ghanem Y, Bedke J, Capitanio U, Dabestani S et al.. European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update. Urol. 2022. Oct;82(4):399–410. doi: 10.1016/j.eururo.2022.03.006 PubMed DOI

Kauffman HM, McBride MA, Cherikh WS, Spain PC, Marks WH, Roza AM. Transplant tumor registry: donor related malignancies. Transplantation. 2002. Aug 15;74(3):358–62. doi: 10.1097/00007890-200208150-00011 PubMed DOI

Cui CB, Gerber DA. Donor-associated malignancy in kidney transplant recipient. J Clin Invest. 2013. Sep;123(9):3708–9. doi: 10.1172/JCI70438 PubMed DOI PMC

Lhotova K, Stolarova L, Zemankova P, Vocka M, Janatova M, Borecka M et al.. Multigene Panel Germline Testing of 1333 Czech Patients with Ovarian Cancer. Cancers (Basel). 2020. Apr 13;12(4):956. doi: 10.3390/cancers12040956 PubMed DOI PMC

Soukupova J, Zemankova P, Lhotova K, Janatova M, Borecka M, Stolarova L et al.. Validation of CZECANCA (CZEch CAncer paNel for Clinical Application) for targeted NGS-based analysis of hereditary cancer syndromes. PLoS One 2018. 13(4):e0195761. doi: 10.1371/journal.pone.0195761 PubMed DOI PMC

Horackova K, Frankova S, Zemankova P, Nehasil P, Cerna M, Neroldova M et al.. Low Frequency of Cancer-Predisposition Gene Mutations in Liver Transplant Candidates with Hepatocellular Carcinoma. Cancers (Basel) 2022. Dec 29;15(1):201. doi: 10.3390/cancers15010201 PubMed DOI PMC

Asch WS, Bia MJ. Oncologic issues and kidney transplantation: A review of frequency, mortality, and screening. Adv Chronic Kidney Dis. 2014. Jan;21(1):106–13. doi: 10.1053/j.ackd.2013.07.003 PubMed DOI

Minkovich M, Wong RBK, Famure O, Li Y, Kim SJ, Lee JY. Renal cell carcinoma in kidney transplant recipients: incidence, trends, clinical management & outcomes. World J Urol. 2023. Sep;41(9):2389–2395. doi: 10.1007/s00345-023-04495-9 PubMed DOI

Chewcharat A, Thongprayoon C, Bathini T, Aeddula NR, Boonpheng B, Kaewput W et al.. Incidence and mortality of renal cell carcinoma after kidney transplantation: A meta-analysis. J Clin Med. 2019. Apr; 8(4): 530. doi: 10.3390/jcm8040530 PubMed DOI PMC

Higgins JP, Troxell ML. Renal cell carcinoma in kidney allografts: histologic types, including biphasic papillary carcinoma. Hum Pathol. 2016. Nov:57:28–36. doi: 10.1016/j.humpath.2016.06.018 PubMed DOI

Tillou X, Guleryuz K, Collon S, Doerfler A. Renal cell carcinoma in functional renal graft: Toward ablative treatments. Transplant Rev (Orlando). 2016. Jan;30(1):20–6. doi: 10.1016/j.trre.2015.07.001 PubMed DOI

Chlupac J, Marada T, Kudla M, Janousek L, Fronek J. Tumor of Transplanted Kidney: Graft Resection Preserves Renal Function with Good Long-Term Oncologic Outcome [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/tumor-of-transplanted-kidney-graft-resection-preserves-renal-function-with-good-long-term-oncologic-outcome/.

Leon G, Szabla N, Boissier R, Gigante M, Caillet K, Verhoest G, et al.. Kidney graft urothelial carcinoma: Results from a multicentric retrospective national study. Urology. 2020. Jan;135:101–105. doi: 10.1016/j.urology.2019.09.015 PubMed DOI

Tillou X, Doerfler A, Collon S, Patard JJ, Badet L, Barrou B et al.. De Novo Kidney Graft Tumors: Results From a Multicentric Retrospective National Study. Am J Transplant. 2012. Dec;12(12):3308–15. doi: 10.1111/j.1600-6143.2012.04248.x PubMed DOI

Szabla N, Matillon X, Calves J, Branchereau J, Champy C, Neuzillet Y et al.. Urology. 2023. Jan:171:152–157. doi: 10.1016/j.urology.2022.09.020 PubMed DOI

Alchoueiry M, Cornejo K, Henske EP. Kidney cancer: Links between hereditary syndromes and sporadic tumorigenesis. Semin Diagn Pathol. 2024. Jan;41(1):1–7. doi: 10.1053/j.semdp.2023.11.002 PubMed DOI

Hickman LA, Sawinski D, Guzzo T, Locke JE. Urologic malignancies in kidney transplantation. Am J Transplant. 2018. Jan;18(1):13–22. doi: 10.1111/ajt.14533 PubMed DOI

Pani A, Porta C, Cosmai L, Melis P, Floris M, Piras D et al.. Glomerular diseases and cancer: evaluation of underlying malignancy. J Nephrol. 2016. Apr;29(2):143–152. doi: 10.1007/s40620-015-0234-9 PubMed DOI PMC

Michel Ortega RM, Wolff DJ, Schandl CA, Drabkin HA. Urothelial carcinoma of donor origin in a kidney transplant patient. J Immunother Cancer. 2016. Oct 18;4:63. doi: 10.1186/s40425-016-0167-4 PubMed DOI PMC

Verneuil L, Varna M, Ratajczak P, Leboef C, Plassa LF, Elbouchtaoui M et al.. Human skin carcinoma arising from kidney transplant-derived tumor cells. Invest. 2013. Sep;123(9):3797–801. doi: 10.1172/JCI66721 PubMed DOI PMC

Singhal K, Watkins MP, Fehniger TA, Griffith M, Griffith OL, Kahl BS, et al.. Donor-Derived Follicular Lymphoma After Kidney Transplantation: A Case Report. JCO Precis Oncol. 2023. Sep:7:e2300177. doi: 10.1200/PO.23.00177 PubMed DOI PMC

Qian Z, Chou E, Yang J, Zhang H, Ye H, Liu ST, et al.. Donor-Derived Urothelial Carcinoma in Renal Transplant Recipients. Case Rep Urol. 2022. Jan 29:2022:3353268. doi: 10.1155/2022/3353268 PubMed DOI PMC

Takeda K, Mittenzwei R, Geisinger KR, Datto MB, Rebellato LM. Donor-Derived Neuroendocrine Carcinoma Transmission to Two Kidney Transplant Recipients Demonstrated by Short Tandem Repeat Analysis: A Case Report. Transplant Proc. 2021. May;53(4):1337–1341. doi: 10.1016/j.transproceed.2021.03.002 PubMed DOI

Desai R, Collett D, Watson CJ, Johnson P, Evans T, Johnson P et al.. Cancer transmission from organ donors-unavoidable but low risk. Transplantation 2012; 94: 1200–1207. doi: 10.1097/TP.0b013e318272df41 PubMed DOI

Nalesnik MA, Woodle ES, Dimaio JM, Vasudev B, Teperman LW, Covington S et al.. Donor-transmit- ted malignancies in organ transplantation: assessment of clinical risk. Am J Transplant 2011; 11: 1140–1147. doi: 10.1111/j.1600-6143.2011.03565.x PubMed DOI

Nieuwenburg SA, Adan F, Ruijs MWG, Sonke GS, van Leerdam ME, Crijns MB. Cumulative risk of skin cancer in patients with Li-Fraumeni syndrome. Fam Cancer. 2020. Oct;19(4):347–351. doi: 10.1007/s10689-020-00178-1 PubMed DOI

You R, Heyang Z, Ma Y, Xia P, Zheng H, Lin J et al.. Identification of biomarkers, immune infiltration landscape, and treatment targets of ischemia-reperfusion acute kidney injury at an early stage by bioinformatics methods. Hereditas. 2022. Jun 4;159(1):24. doi: 10.1186/s41065-022-00236-x PubMed DOI PMC

Poveda J, Sanz AB, Rayego-Mateos S, Ruiz-Ortega M, Carrasco S, Ortiz A, et al.. NFκBiz protein downregulation in acute kidney injury: Modulation of inflammation and survival in tubular cells. Biochim Biophys Acta. 2016. Apr;1862(4):635–646. doi: 10.1016/j.bbadis.2016.01.006 PubMed DOI

Liu Z, Tang C, He L, Yang D, Cai J, Zhu J et al.. The negative feedback loop of NF-κB/miR-376b/NFKBIZ in septic acute kidney injury. JCI Insight. 2020. Dec 17;5(24):e142272. doi: 10.1172/jci.insight.142272 PubMed DOI PMC

Chung KW, Jeong HO, Lee B, Park D, Kim DH, Choi YJ et al.. Involvement of NF-κBIZ and related cytokines in age-associated renal fibrosis. Oncotarget. 2017. Jan 31;8(5):7315–7327. doi: 10.18632/oncotarget.14614 PubMed DOI PMC

Abedini A, Ma Z, Frederick J, Dhillon P, Balzer MS, Shrestha R et al.. Spatially resolved human kidney multi-omics single cell atlas highlights the key role of the fibrotic microenvironment in kidney disease progression. bioRxiv, 2022: p. 2022.10.24.513598.

Affo S, Yu LX, Schwabe RF. The Role of Cancer-Associated Fibroblasts and Fibrosis in Liver Cancer. u Rev Pathol. 2017. Jan 24:12:153–186. doi: 10.1146/annurev-pathol-052016-100322 PubMed DOI PMC

Fayer S, Horton C, Dines JN, Rubin AF, Richardson ME, McGoldrick K et al.. Closing the gap: Systematic integration of multiplexed functional data resolves variants of uncertain significance in BRCA1, TP53, and PTEN. Am J Hum Genet. 2021. Dec 2;108(12):2248–2258. doi: 10.1016/j.ajhg.2021.11.001 PubMed DOI PMC

Lucci-Cordisco E, Amenta S, Panfill A, Del Valle J, Capellá G, Pineda M, et al.. Variants of uncertain significance (VUS) in cancer predisposing genes: What are we learning from multigene panels? Eur J Med Genet. 2022. Jan;65(1):104400. doi: 10.1016/j.ejmg.2021.104400 PubMed DOI

Makhoon S, Levin B, Ensinger M, Mattie K, Volk RJ, Zhao Z et al.. A multicenter study of clinical impact of variant of uncertain significance reclassification in breast, ovarian and colorectal cancer susceptibility genes. Cancer Med. 2023. Feb;12(3):2875–2884. doi: 10.1002/cam4.5202 PubMed DOI PMC

Chen E, Facio FM, Aradhya KW, Rojahn S, Hatchell KE, Aguilar S et al.. Rates and Classification of Variants of Uncertain Significance in Hereditary Disease Genetic Testing. JAMA Netw Open. 2023. Oct 2;6(10):e2339571. doi: 10.1001/jamanetworkopen.2023.39571 PubMed DOI PMC

Lahtinen AK, Koski J, Ritari J, Hyvärinen K, Koskela S, Partanen J et al.. Clinically relevant germline variants in allogeneic hematopoietic stem cell transplant recipients. Transplant. 2023. Jan;58(1):39–45. doi: 10.1038/s41409-022-01828-x PubMed DOI PMC

Soraru J, Chakera A, Isbel N, Mallawaarachichi A, Rogers N, Trnka P et al.. The evolving role of diagnostic genomics in kidney transplantation. Kidney Int Rep. 2022. May 25;7(8):1758–1771. doi: 10.1016/j.ekir.2022.05.019 PubMed DOI PMC

Chavarri-Guerra Y, Slavin TP, Longoria-Lozano O, Weitzel JN. Genetic cancer predisposition syndromes among older adults. J Geriatr Oncol. 2020. Sep;11(7):1054–1060. doi: 10.1016/j.jgo.2020.01.001 PubMed DOI PMC

NCCN. Genetic/familial high-risk assessment: breast, ovarian, and pancreatic, version 3.2024, NCCN clinical practice guidelines in oncology. [on-line]. Available from: https://www.nccn.org/guidelines/category_2. PubMed

Sessa C, Balmana J, Bober SL, Cardoso MJ, Colombo N, Curigliano G et al.. Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline. Ann Oncol 2023; 34(1): 33–47. doi: 10.1016/j.annonc.2022.10.004 PubMed DOI

Kleiblova P, Novotny J, Cibula D, Curtisova V, Dubova O, Foretova L et al.., Doporučené postupy klinické péče o nosiče zárodečných mutací v genech BRCA1, BRCA2, PALB2, ATM a CHEK2 predisponujících ke vzniku dědičného karcinomu prsu, vaječníků, prostaty a pankreatu (4.2024). Klin Onkol 2024; 37(4): 292–299. PubMed

ÚZIS. Zdravotnická ročenka české republiky 2021. [on-line]. Available from: https://www.uzis.cz/index.php?pg=vystupy—knihovna&id=275.

Bertolotto C, Lesueur F, Giuliano S, Strub T, de Lichy M, Bille K et al.. A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma. Nature. 2011. Oct 19;480(7375):94–8. doi: 10.1038/nature10539 PubMed DOI

Woodward ER, Skytte AB, Cruger DG, Maher ER. Population-based survey of cancer risks in chromosome 3 translocation carriers. Genes Chromosomes Cancer. 2010. Jan;49(1):52–8. doi: 10.1002/gcc.20718 PubMed DOI